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BY-NC-ND license (http://creativecomBackground/Purpose: Carcinoembryonic antigen (CEA) is an attractive target for immuno-
therapy because it is expressed minimally in normal tissue, but is overexpressed in a wide va-
riety of malignant epithelial tissues. Lactic acid bacteria (LABs), widely used in food processes,
are attractive candidates for oral vaccination. Thus, we examined whether LABs could be used
as a live vaccine vector to deliver CEA antigen.
Methods: CEA was cloned into an Escherichia coli/Lactococcus lactis shuttle vector pSEC:LEISS
under the control of a nisin promoter. For displaying the CEA on the cell surface of the L. lactis
strain, the anchor motif LcsB from the S-layer protein of Lactobacillus crispatus was fused with
CEA. Intracellular and cell surface expression of the CEAeLcsB fusion was confirmed by west-
ern blot analysis.
Results: Significantly higher levels of CEA-specific secretory immunoglobulin A in the sera of
mice were observed upon oral administration of strain cultures containing the CEAeLcsB fused
protein. In addition, the CEAeLcsB antigen group showed a higher spleen index compared to
the CEA antigen alone or negative control, demonstrating that surface-displayed CEA antigen
could induce a higher immune response.ng, Health Science Exchange and Service Center of Jinan, Linongzhuang road 33, Jinan 250013, China.
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852 X. Zhang et al.Conclusion: These results provided the first evidence for displaying CEA antigen on the cell sur-
faces of LABs as oral vaccines against cancer or infectious diseases.
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Carcinoembryonic antigen (CEA), which was first identified
in human colon cancer in 1963, is a 180-kDa glycoprotein.
Normally, CEA can be expressed in limited areas of the
adult human body, but it is overexpressed in a high per-
centage of adenocarcinomas, particularly in those of the
colon, pancreas, breast, lungs, rectum, and stomach.
Hence, CEA is used as a tumor-related marker at clinic
diagnosis.1,2 Previous studies have proved that CEA has high
immunogenicity and can elicit strong T-cell and humoral
immune responses, which are helpful in inhibiting the
growth of malignant tumors in vivo.3 Apparently, develop-
ment of a CEA-based vaccine to induce potent T-cell im-
munity will be significant in the immunotherapy of tumors.
Many strategies for development of CEA-based vaccines
have been reported, including recombinant live vector
vaccines (viral and/or bacterial vector vaccines), nucleic
acid vaccines (DNA and/or RNA replicon vaccines), and
protein or peptide vaccines.4e8 Viral vectors or DNA vac-
cines offer the ability to deliver antigen into the cytosol,
and therefore into the conventional major histocompati-
bility complex (MHC) class I processing pathway. However,
concern about the disadvantages, including the limited DNA
carrying capacity, toxicity, immunogenicity, the possibility
of random integration of the vector DNA into the host
genome, and their high coat, may limit the application of
viral and DNA vaccines.9,10 Thus, to circumvent these is-
sues, the use of live, food-grade, noninvasive, nonpatho-
genic bacteria as antigen vehicles is a promising strategy.
Lactic acid bacteria (LABs) are generally regarded as
safe microorganisms, and some of them are able to stimu-
late the immune system of the host as adjuvants due to
their probiotic properties and their immunomodulation
capacity, which makes them advantageous live vac-
cines.11,12 Among LABs, Lactococcus lactis is, by far, the
most extensively studied with respect to its physiology,
metabolic pathways, and regulatory mechanisms, and its
genome was the first LAB genome to be completely
sequenced and annotated.13 Because of its ability to pass
through the intestinal tract without colonization, the use of
L. lactis as a vaccine vector is emerging as one of the most
advanced prototypes of a possible new class of bacterial
vaccines derived from noninvasive, nonpathogenic Gram-
positive bacteria.11,14,15 Immunization with L. lactis-deliv-
ered vaccines elicits immune responses specific to heter-
ologous antigens.16,17 To date, many expression systems
have been developed to produce recombinant proteins for
various biotechnological applications in LABs. The best-
characterized controllable expression system is based on
the use of the nisin biosysthesis promoter pnisA. This sys-
tem is versatile and can be used to produce large quantitiesof prokaryotic and eukaryotic proteins because there is a
linear dependency between the amount of nisin added to
the culture medium and the promoter activity.18 Several
antigens (e.g., L7/L12, TTFC, HA, and capsid protein of
PCV) have been successfully expressed using the NICE sys-
tem (nisin-controlled gene expression) or its de-
rivatives.16,17,19,20 Note that a protective immune response
depends not only on the antigen and the delivery vehicle,
but also on the location of the antigen.19 Various genetic
engineering tools have been developed to express antigens
and therapeutic molecules efficiently at different cellular
localizations (i.e., cytoplasm, cell wall, or extracellular
medium).19,21 To display antigen on the cell surface of L.
lactis cells, various anchoring motifs, such as LysM and
LcsB, as well as M6 protein, have also been explored for
their efficiency in attaching hybrid protein to the cell
membrane or cell wall of LABs.19,22e24
In this work, we constructed genetically modified L.
lactis that produced recombinant CEA antigen by using the
NICE system. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and western blotting showed
that CEA was displayed on the cell surface of L. lactis under
the aid of the anchoring motif LcsB. Immunization analysis
demonstrated that the surface-displayed CEA induced an
immune response according to activation of the spleen and
secretion of immunoglobulin A (IgA).
Methods
Bacterial strains and growth conditions
All of the strains, plasmids, and oligonucleotide primers
used in this study are described in Table 1. L. lactis NZ9000
was grown in M17 broth (Oxoid, Basingstoke, Hants, UK)
supplemented with 0.5% (w/v) glucose (GM17) at 30C or
42C anaerobically, respectively. Escherichia coli DH5a was
grown aerobically in LuriaeBertani broth at 37C. Chlor-
amphenicol was used at 10 mg/mL and 5 mg/mL for E. coli
and L. lactis, respectively.
BALB/c mice (6e8 weeks old; Medical Experimental
Center of Shandong University, China) were housed in a
pathogen-free isolator under sterile conditions in the ani-
mal facilities of Jinan Health Science Exchange and Service
Center (China). All experiments were performed according
to protocols in accordance with institutional guidelines.
Plasmids and DNA manipulations
Standard recombinant DNA techniques were performed as
described previously.23 Electroporation of L. lactis was
performed using a Gene Pulser (2500 V, 200 U, 25 mF, 5 ms,
Table 1 Strains, plasmids and primers used in this study
Strain, plasmid, or primer Relevant characteristics a Refs
Strains
E. coli DH5a supE44DlacU169480lacZDM15hsdR17recA1endA1gyrA96thi-1relA1 Novagen
L. lactis NZ9000 MG1363 pepN::nisRK. Most commonly used host of the NICE system 20
Plasmids
pSEC:LEISS GK:Cmr; mature Nuc fused at 50 end with sequence of propeptide LEISSTCDA 20
pMD18-T-S pMD18-T containing slpB of Lactobacillus crispatus K2-4-3 26
pMD18-T-cea pMD18-T containing cea of HT-29 cells This study
pSEC:LEISS-Cea pSec:Leiss:Nuc(NsiI/HindII::cea) This study
pSEC:LEISS-Cea2 pSec:Leiss:Nuc(NsiI/EcoRI::cea2) This study
pSEC:LEISS-Cea-LcsB pSec:Leiss:Nuc(EcoRI/HindIII::cea2-lcsB) This study
Primers
CEA-NsiI 50-GCTATGCATCCATGGAGTCTCCCTCGGCCCCT-30 This study
CEA-ClaI 50-CCAATCGATCTATATCAGAGCAACCCCAACCAG-30 This study
CEA-NsiI&NcoI 50-GAGATATCGTCGACTTGTGATGCAT-30 This study
CEA-EcoRI 50-CAG AATTCTATCAGAGCAACCCCAACCA-30 This study
LcsB-EcoRI 50-GAGAATTCAATTGGTTCGTTGCACCTAAG-30 This study
LcsB-HindIII: 50-GCGAAGCTTTTAAAAGTTTGAAGCCTTTACG-30 This study
The development of CEA oral vaccine 853Bio-Rad Laboratories, USA) as described previously.25 Po-
lymerase chain reaction (PCR) products were generated
using rTaq polymerase (TaKaRa, Tokyo, Japan).
Cea gene was PCR amplified by primers CEA-NsiI/CEA-
ClaI using the cDNA of HT-29 cells as template.26 The PCR
products were ligated into pMD18-T, resulting in the pMD18-
T-cea vector. Plasmids were extracted using Plasmid Mini
Mix (Omega, GA, USA) and sent to the Beijing Genomics
Institute (BGI, China) for sequencing.
The different CEA expression vectors are described in
Fig. 1. The cea fragments were digested from pMD18-T-cea
vector with NsiI and HindIII, and ligated into the NsiI/HindIII
digested plasmid pSEC:LEISS, generating the pSEC:LEISS-
Cea vector. Cea was PCR amplified with primers CEA-NsiI
or NcoI and CEA-EcoRI using the pSEC:LEISS-Cea as tem-
plates. The PCR products were digested with NsiI/EcoRI and
cloned into NsiI/EcoRI digested pSEC:LEISS vector, yielding
plasmid pSEC:LEISS-Cea2. The LcsB fragments were PCR
amplified using primers LcsB-EcoRI and LcsB-HindIII from
pMD18-S. The resulting PCR products were digested with
EcoRI/HindIII and cloned into the corresponding site of
pSEC:LEISS-Cea2, resulting in the recombinant plasmid
pSEC:LEISS-Cea-LcsB. Transformation of L. lactis by elec-
troporation was performed as described previously,22
resulting in the recombinants, L. lactis/pSEC:LEISS, L. lac-
tis/pSEC:LEISS-Cea, and L. lactis/pSEC:LEISS-Cea-LcsB,
respectively.
Expression and extraction of nisin-induced proteins
in L. lactis
Gene expression was carried out as described previously.23
L. lactis NZ9000 harboring the recombinant plasmids con-
structed above were grown overnight at 37C in GM17 me-
dium containing 5 mg/mL chloramphenicol. Subsequently,
the overnight cultures were 100-fold diluted in 1 L fresh
GM17 medium with 5 mg/mL chloramphenicol, and incu-
bated until the cell density reached 0.4 (at 600 nm). Then,nisin (Sigma, St Louis, MO, USA) was added to cultures at a
final concentration of 10 ng/mL. Growth was continued for
7 hours at 18C to induce protein expression.
The extraction of proteins from L. lactis was performed
as described by Hu et al.23 The supernatant fraction was
obtained according to the trichloroacetic acid/acetone
method. Briefly, 100 mL 100% trichloroacetic acid was mixed
with 1 mL supernatant for protein precipitation. Subse-
quently, the mixtures were vortexed for 15 seconds and
placed on ice for 15 minutes. The pellets of protein were
obtained by centrifugation at 14,000 g for 10 minutes and
washed twice with 100 mL acetone. After drying in air, the
pellets were dissolved in 50 mlL 1  SDS loading buffer.
Membrane and cell wall fractions were isolated from 10-
mL cultures of L. lactis induced by nisin at 18C for 6 hours
as follows. The cells from 10 cultures were harvested and
resuspended in 10 mL phosphate-buffered saline (PBS).
After disrupting the cells by sonication on ice at 400 W for
three cycles (one cycle consisted of 50 times sonication for
3 seconds, with 8-second intermissions), the resuspended
cells were centrifuged for 10 minutes at 10,000 g to remove
cell debris. The resulting supernatants were centrifuged for
30 minutes at 100,000 g and the membrane and cell wall
fractions were recovered in the pellet, which were resus-
pended in 50 mL PBS and mixed with 1  SDS-PAGE buffer.
The sample was incubated at 37C for 5 minutes before
electrophoresis in standard 12% SDS-PAGE.
Western blotting
The proteins separated by 12% SDS-PAGE were electrically
transferred onto a polyvinylidene fluoride membrane at
200 mA for 1.5 hours in an ice-water bath. The membrane
was washed with TBST buffer [Tris Buffered Saline with
Tween, 20mM TriseHCl (pH 7.4), 500mM NaCl, 0.01% Tween
20) three times for 15 minutes each in an ice bath and
blocked in blocking buffer (TBST buffer with 5% nonfat
milk) for 1 hour at room temperature. The membrane was
Figure 1. (A) A schematic construction of the expression vectors pSEC:LEISS-Cea, pSEC:LEISS-Cea2, and pSEC:LEISS-Cea-LcsB. (B)
PCR products of CEA and CEAeLcsB gene fragments. Lane M, DNA markers; Lane 1, PCR products of CEA gene; Lane 2, the CEA-LcsB
gene. CEA Z carcinoembryonic antigen; PCR Z polymerase chain reaction.
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bated overnight with the primary anti-CEA polyclonal
antibody (eBioscience, California, USA) at a dilution of
1:600. Subsequently, the membrane was washed three
times in TBST, and incubated with horseradish peroxidase
(HRP)-coupled secondary antibody (Solarbio, Beijing,
China) at a dilution of 1:5000 with TBST buffer containing
5% nonfat milk powder for 1 hour. The membrane was
washed as above. The chromogenic reaction was termi-
nated with distilled water after 1 minute using DAB (3,3-
diaminobenzidine)/NiCl2 as the chromogenic agent.
Vaccination with CEA
Cultures of the strain L. lactis/pSEC:LEISS, L. lactis/pSE-
C:LEISS-Cea, and L. lactis/pSEC:LEISS-Cea-LcsB were grown
and induced as described above. Cells from 10-mL cultures
were harvested and resuspended in PBS to a final concen-
tration of 109 colony-forming units (CFU)/mL for L. lactis/
pSEC:LEISS and L. lactis/pSEC:LEISS-Cea. For L. lactis/pSEC:LEISS-Cea-LcsB, the cell densities were adjusted to a
series of concentrations of 108 CFU/mL, 109 CFU/mL and
1010 CFU/mL, respectively.
Immunization of mice
BALB/c mice (6e8 weeks old) were obtained from the
Medical Experimental Centre of Shandong University and
divided into six groups (PBS, L. lactis/pSEC:LEISS, L. lactis/
pSEC:LEISS-Cea, 108 CFU/mL L. lactis/pSEC:LEISS-Cea-LcsB,
109 CFU/mL L. lactis/pSEC:LEISS-Cea-LcsB, and 1010 CFU/
mL L. lactis/pSEC:LEISS-Cea-LcsB). Each group contained 12
mice. Doses of 0.5 mL were administered orally to each
group on Days 1, 4, 7, 14, 21, 28, and 35. One week after the
last administration, thymus and spleen were collected and
weighed to compare the thymus index and spleen index for
those groups. Sera and intestinal washings were collected to
evaluate the immunogenicity with enzyme-linked immuno-
sorbent assay (ELISA). The small intestine was collected and
cut into 1-cm pieces. The intestines were suspended in 1 mL
The development of CEA oral vaccine 855PBS and vortexed for 30 seconds. After centrifugation at
12,000 g for 20 minutes, supernatants were collected and
stored at 80C.
Analysis of antibody response
ELISA was used to determine serum immunoglobulin G (IgG)
and fecal secretory IgA (sIgA) antibody responses. Flat
transparent 96-well microtiter plates (Costar, Maine, USA)
were coated overnight at 4C with 80 mL purified CEA pro-
tein per well at a concentration of 50 ng/mL in three par-
allel groups. After washing three times with PBST (PBS
containing 0.05 % Tween 20), the wells were blocked with
100 mL PBST containing 5% non-fat milk powder at 4C for 8
hours. Twenty-five-fold dilutions of sera were applied and
incubated at 37C for 1 hour after being washed three times
with PBST. The wells were washed again and 80 mL HRP-
conjugated antimouse IgG antibodies was added (g-chain
specific; SigmaeAldrich, Steinheim, Germany) at 1:2000
dilutions, and incubated for 1 hour at 37C. The wells were
washed again and incubated with 100 mL 3,30,5,50-tetra-
methylbenzidine substrate (SigmaeAldrich) for 10 minutes
at room temperature avoiding light. Color reaction was
terminated by the addition of 50 mL 2M H2SO4 and absor-
bances were read at 450 nm.
ELISA was performed essentially as described for serum
samples, with minor modifications as follows. Purified CEA
protein at a concentration of 5 mg/mL, and 100-fold dilution of
intestinal washings were applied and HRP-conjugated anti-
mouse IgA antibodies (a-chain specific; SigmaeAldrich) at
1:2000dilutionwereused insteadofantimouse IgGantibodies.
Statistical analysis
One-way analysis of variance (SAS, version 6.03) was per-
formed to find significant differences among various pa-
rameters. A significance level of p < 0.05 was used.Figure 2. Expression and fractionation of recombinant CEA prote
in Lactococcus lactis NZ9000 by (A) sodium dodecyl sulfate polyac
Protein marker; Lane 1, total proteins in L. lactis harboring pSEC:LE
Lane 3, total proteins in L. lactis harboring pSEC:LEISS-Cea-LcsB;
LcsB. CEA Z carcinoembryonic antigen.Results
Cloning and characterization of CEA gene
The whole cea gene was obtained from the cDNA of HT-29
cells, which was extracted previously in our laboratory.26
The cea consisted of 1872 bp that encoded a polypeptide
of 623 amino acid residues, which shared 99% identity with
CEA-related cell adhesion molecule 5.
Expression of CEA in L. lactis
The pSEC:LEISS vector, which contained the Usp45 signal
peptide (Usp45 is the major secreted protein of L. lactis)
and synthetic oligopeptide LEISSTCDA (called Leiss), was
used in this study. To express and target CEA on the surface
of L. lactis, the LcsB anchor motif, the C-terminal region of
SlpB of Lactobacillus crispatus K2-4-3 that served as a
functional scaffold to target the heterologous proteins to
the cell surfaces of LABs in vitro and in vivo, was fused to
CEA.23 Expression of CEA and CEAeLcsB was confirmed by
SDS-PAGE and western blot analysis using the CEA-specific
polyclonal antibody. As shown in Fig. 2, the obvious bands
of CEA (69 kDa, Lane 1) and CEAeLcsB (89 kDa, Lane 3)
were observed at the estimated size, suggesting that CEA
was successfully expressed in L. lactis. Moreover, an
obvious band, representing the CEAeLcsB fusions, was
clearly visible in the membrane and cell wall fractions
(Fig. 2B, Lane 4), indicating that CEA was displayed on the
cell walls of L. lactis with the aid of LcsB motif.
Oral immunization, thymus index and spleen index
After immunizing mice six times over a 5-week period,
thymus and spleen were collected and weighed to deter-
mine the thymus index and spleen index for the six groups.ins synthesized from pSEC:LEISS-Cea and pSEC:LEISS-Cea-LcsB
rylamide gel electrophoresis and (B) western blot analysis. M,
ISS; Lane 2, total proteins in L. lactis harboring pSEC:LEISS-Cea;
Lane 4, surface proteins in L. lactis harboring pSEC:LEISS-Cea-
Figure 3. (A) Spleen index and (B) thymus index of mice orally immunized with phosphate-buffered saline, Lactococcus lactis
CEA, or CEAeLcsB. CEA Z carcinoembryonic antigen.
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antigen concentration by gavage (Fig. 3). The spleen index
in Group 6, which was orally administered 1010 CFU/mL
L. lactis/pSEC:LEISS-Cea-LcsB cells, was significantly higher
than in the control group (p < 0.05). Meanwhile, the
thymus index of each group of mice did not obviously differ
among the groups. These results indicated that oral gavage
did not significantly affect the mouse thymus index.
Immune response in mice against CEA
To examine the immunogenicity of CEA, sera and intestinal
washings were collected for ELISA analysis to determine
sera IgG and intestinal washings sIgA antibody responses. As
shown in Fig. 4, L. lactis/pSEC:LEISS-Cea-LcsB with
different cell densities showed a significant sIgA response,
while no significant sIgA response was found in L. lactis/
pSEC:LEISS and L. lactis/pSEC:LEISS-Cea (Fig. 4A), sug-
gesting that only the surface-displayed CEA induced hosts
to produce specific anti-CEA antibody of sIgA. However, no
obvious difference in the value of sera IgG was found, whichFigure 4. (A) CEA-specific mucosal secretory IgA and (B) serum Ig
orally immunized with phosphate-buffered saline or Lactococcus lacmay have been because of the lack of immune time or
fewer immune times.Discussion
LABs possess a number of properties that make them
attractive candidates for oral vaccination. These bacteria
have been used for centuries in the fermentation and
preservation of food, and are considered to be safe or-
ganisms with a GRAS (Generally Recognized As Safe) sta-
tus.11 L. lactis, a model LAB, is a potential candidate for
the production of biologically useful proteins.21 Protein
production in L. lactis for oral vaccines offers several ad-
vantages: L. lactis produces low amounts of native exo-
proteins and it does not colonize the digestive tract of
humans or animals, but can survive passage through the
gut.14,15 Thus, a transient presentation of the antigen to
the mucosal immune system by noncommensal bacteria
may avoid the risk of immunotolerance. Furthermore, L.
lactis is approximately the same size as biodegradableG detected by enzyme-linked immunosorbent assay from mice
tis CEA or CEAeLcsB strains. CEAZ carcinoembryonic antigen.
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effective oral vaccine vehicles.27,28 In this study, we first
developed a CEA vaccine based on live recombinant L.
lactis that produced CEA on the surface of L. lactis cells.
The production of a desired antigen by L. lactis can occur
in three locations: intracellular, extracellular, and cell wall
anchored. Extracellular antigen results in direct interaction
with the environment. Cell-wall anchored antigen, not only
interacts directly with the environment, but also can avoid
proteolytic degradation.21 In this study, only the surface-
displayed CEA induced the gut to produce specific anti-
CEA antibody of sIgA, confirming that the surface-
displayed antigens on the L. lactis cells were more resis-
tant to proteolysis and easily taken up by the epithelial M
cells of the small intestine.16,29 To date, many anchor motifs
were exploited to target the heterologous proteins to the
cell surface of LABs, such as LPXTG (conserved Leu-Pro-X-
Thr-Gly)-containing proteins, transmembrane protein PgsA,
LysM motif-containing proteins, and S-layer proteins.11,24
However, most surface display systems for vaccine appli-
cations are limited in the size of foreign antigens they can
display. A previous study has shown that LcsB has the ability
to locate the heterologous proteins (green fluorescent pro-
tein 27 kDa, b-galactosidase 66 kDa) on the cell surface,
indicating that LcsB can carry amino acid insertions of up to
500 residues to the cell surface.23 Therefore, LcsB was used
as the anchor motif to target the CEA on the surface of the
L. lactis cells. The results here showed that LcsB displayed
the CEA protein on the surface of L. lactis cells, resulting in
an obvious band in the membrane and cell wall fractions
(Fig. 2B, Lane 4). This was also the first evidence to display
CEA on the cell wall of L. lactis with the aid of LcsB.
CEA is an attractive target for immunotherapy because it
is expressed minimally in normal tissue, but is overex-
pressed in a wide variety of malignant epithelial tissues.1,2
This study demonstrated for the first time that the surface-
displayed CEA in L. lactis can induce immune responses.
The spleen, which contains a large number of lymphocytes
and macrophages, is the largest immune organ, and exerts
an antitumor effect through a variety of mechanisms. As
shown in Fig. 3A, the mouse spleen index in Group 6, which
was orally administered 1010 CFU/mL L. lactis/pSEC:LEISS-
Cea-LcsB cells, was significantly higher than in the control
group (p < 0.05), indicating that the surface-displayed CEA
activated the spleen. Moreover, recombinant CEA improved
secretion of specific sIgA according to activated lymphoid
tissue of intestinal mucosa and increased immune function
of gastrointestinal mucosa, thus exerting significant effects
on antiallergic, anti-inflammatory and antitumor activity.
Unfortunately, the recombinant CEA in L. lactis did not
induce serum IgG (Fig. 4B). This might have been because
serum IgG was produced slowly or serum IgG had not yet
reached a detectable titer.
In conclusion, the surface-displayed CEA constructed
here effectively induced the immune response, providing
the possibility of the use of L. lactis CEA in vaccination
protocols against cancer or infectious diseases.Conflicts of interest
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